Ambalal Sarabhai Enterprises Limited (BOM:500009)
India · Delayed Price · Currency is INR 38.13
-0.02 (-0.05%)
At close: Oct 16, 2026
BOM:500009 Revenue
Ambalal Sarabhai Enterprises had revenue of 435.63M INR in the quarter ending June 30, 2026, with 7.99% growth. This brings the company's revenue in the last twelve months to 2.06B, up 4.46% year-over-year. In the fiscal year ending March 31, 2026, Ambalal Sarabhai Enterprises had annual revenue of 2.03B with 2.64% growth. That makes Ambalal Sarabhai Enterprises the 33,274th largest company in the world by revenue and 2,488th in India.
Revenue (ttm)
2.06B
Revenue Growth
+4.46%
P/S Ratio
1.42
Revenue / Employee
3.76M
Employees
547
Market Cap
2.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.03B | 52.02M | 2.64% |
| Mar 31, 2025 | 1.97B | 230.03M | 13.20% |
| Mar 31, 2024 | 1.74B | 32.87M | 1.92% |
| Mar 31, 2023 | 1.71B | -266.02M | -13.46% |
| Mar 31, 2022 | 1.98B | 324.75M | 19.66% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 7.73B |
| Medicamen Biotech | 2.06B |
| Sat Kartar Life | 2.01B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
| Jenburkt Pharmaceuticals | 1.69B |
| Astonea Labs | 1.48B |
| BDH Industries | 997.10M |
Ambalal Sarabhai Enterprises News
- 7 months ago - EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity - Benzinga